AVADIM TECHNOLOGIES INC. INKS $14 MILLION INSTITUTIONAL FINANCING TERM SHEET TO CONTINUE ACCELERATION OF ITS BUSINESS PLAN

Asheville, NC (November 13, 2017)—Avadim Technologies Inc. (“Avadim”), the Bionome Therapies™ life sciences company, today announced the execution of a $14 million private financing term sheet with GPB Debt Holdings II, LLC (“GPB”), an institutional investor located in New York, NY, subject to customary due diligence and closing conditions.Both Avadim and the GPB are working  to sign a definitive agreement and close the transaction with an anticipated closing of December 15th, 2017. This term sheet also allows Avadim to raise an additional $5 million from other sources.

Steve Woody, the CEO of Avadim, said “We are pleased to be in partnership with GPB, who will be providing Avadim the additional capital to accelerate the development of the company’s innovative technology platform and expand our sales efforts. Having an institutional investor achieves another milestone for the company and its plan to go public.”

About Avadim Technologies Inc.

Based in Asheville NC, Avadim Technologies, Inc. is the Bionome Life Science company.  Avadim’s patented platform technology drives the company’s development and marketing of topical, low pH, microbiome-compliant formulations which address multiple applications in both clinical patient care and consumer health.  Our innovative approaches to neuromuscular health and performance, and to multiple skin-related patient care challenges, are safe, non-centrally acting, and cost effective, and are changing markets and improving lives.

Avadim Technologies Inc. Contacts:

David Fann, President

828.251.7111 Office

904.251.4910 Cell

[email protected]

Joe McGuire, Chief Financial Officer

828.251.7111 Office

904.228.2603 Cell

[email protected]

Avadim Technologies Inc.

81 Thompson Street

Asheville, NC 28803

www.avadimtechnologies.com

Investor Relations:

KCSA Strategic Communications

Valter Pinto

212.896.1254

www.kcsa.com

Media Contact:

Liz White

Kel & Partners

[email protected]

O: 617.904.9393, ext. 151

C: 978.621.9281